HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Poster communications

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

Document type :
Poster communications
Complete list of metadata

https://hal.univ-brest.fr/hal-01950797
Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Tuesday, December 11, 2018 - 9:26:15 AM
Last modification on : Tuesday, April 12, 2022 - 5:00:02 PM

Identifiers

  • HAL Id : hal-01950797, version 1

Collections

Citation

P. Hilliquin, T Barnetche, G Baudens, R. Niarra, I Idier, et al.. Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis. ACR/ARHP Annual Meeting, Oct 2018, Chicago, France. 70 (suppl 10) (Abstract 573), Arthritis Rheumatology. ⟨hal-01950797⟩

Share

Metrics

Record views

21